PROCEPT BioRobotics Corporation $PRCT Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in PROCEPT BioRobotics Corporation ($PRCT) during Q4, acquiring an additional 49,457 shares to hold a total of 84,294 shares valued at $2.65 million. Despite this institutional buying and overall insider net purchases, the company reported a Q4 earnings miss and revenue below expectations, leading to a mixed analyst consensus of "Hold" with a target price of $40.82. The article highlights other institutional movements and recent insider sales by two EVPs, even as insiders were net buyers over the quarter.
PRCT Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Procept Biorobotics Corp (PRCT), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company generates most of its revenue from Hand pieces and other consumables, holds a 60.63% gross margin, but shows negative operating and net margins. It also benchmarks PRCT's gross margin against industry rivals ATRC and TNDM.
Will Aquablation’s Strong EU Guideline Backing Reshape PROCEPT BioRobotics’ (PRCT) Long-Term Narrative?
The European Association of Urology's strong recommendation for Aquablation therapy for benign prostatic hyperplasia (BPH) is expected to significantly impact PROCEPT BioRobotics (PRCT). This endorsement, backed by clinical evidence, could boost the adoption of Aquablation and its HYDROS platform in hospitals, especially in Europe. Investors are now re-evaluating PRCT's long-term potential, considering the balance between increased clinical validation and ongoing risks like reimbursement pressures and profitability challenges.
Prosight Management, LP's PROCEPT BioRobotics Corp(PRCT) Holding History
This article details Prosight Management, LP's historical holding in PROCEPT BioRobotics Corp (PRCT). As of December 31, 2025, Prosight Management held 1.38 million shares valued at $43.41 million, constituting 8.97% of their portfolio. The firm shows an estimated loss of $12.30 million (a -25.94% gain) on its PRCT holdings.
Trading the Move, Not the Narrative: (PRCT) Edition
This article analyzes Procept Biorobotics Corporation (NASDAQ: PRCT), highlighting stable neutral readings in shorter timeframes that could indicate an easing of a long-term weak bias. It outlines an exceptional 110.2:1 risk-reward setup targeting a 29.4% gain, along with institutional trading strategies tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis and details AI-generated signals for PRCT.
Truist Lowers PT on PROCEPT BioRobotics Corporation (PRCT) to $50 From $64, Keeps a Buy Rating
Truist has reduced its price target for PROCEPT BioRobotics Corporation (PRCT) shares to $50 from $64. Despite this significant cut, the firm has maintained its "Buy" rating on the stock. This adjustment suggests a revised valuation for the company while still recommending its purchase.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of "Hold" by Brokerages
PROCEPT BioRobotics (NASDAQ:PRCT) has received a consensus "Hold" rating from fourteen analysts, with an average one-year price target of $40.82. The company recently reported a fourth-quarter EPS of ($0.53) and revenue of $76.4 million, both missing analyst expectations. Insider activity shows more purchases than sales, and institutional investors own 89.46% of the company's stock.
PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Up 6.6% - Still a Buy?
PROCEPT BioRobotics (NASDAQ:PRCT) saw its stock price increase by 6.6% during mid-day trading despite recent analyst target trims and a consensus "Hold" rating. The company missed quarterly earnings and revenue expectations, though revenue was up 11.9% year-over-year. Insider buying, strong liquidity, and low debt-to-equity ratios are noted, with institutional investors owning a significant portion of the stock.
Vanguard Realigns Reporting; PROCEPT BioRobotics (PRCT) Beneficial Ownership 0%
The Vanguard Group has filed an amended Schedule 13G/A for PROCEPT BioRobotics Corp (PRCT), reporting 0% beneficial ownership due to an internal realignment effective January 12, 2026. This realignment, guided by SEC Release No. 34-39538, means certain Vanguard subsidiaries will now report beneficial ownership separately. The filing clarifies that Vanguard itself no longer holds beneficial ownership over these consolidated holdings, although the investment strategies remain the same.
PROCEPT BioRobotics (PRCT) Strengthens Its Case with Expanding System Base
PROCEPT BioRobotics Corp. (PRCT) is highlighted as a top pure-play robotics stock due to its focus on robotic-assisted surgical systems for urologic procedures. The company recently launched its HYDROS robotic system internationally, starting with the UK, and reported strong Q4 and full-year 2025 revenues with positive growth projections for FY 2026, driven by an expanding global system base. The article suggests that while PRCT is a promising investment, there might be other AI stocks with even higher, shorter-term return potential.
PROCEPT BioRobotics outlines $325.5M 2025 revenue target amid leadership transition and margin expansion
PROCEPT BioRobotics announced a significant revenue target of $325.5 million for 2025, alongside a leadership transition as CEO Reza Zadno steps down and assumes a new role as CEO-Emeritus. The company also projects gross margin expansion, aiming for a 73-75% margin in 2025 by leveraging increased procedural efficiency and optimizing Aquabeam console placement. These strategic moves are intended to enhance profitability and solidify market position.
PROCEPT BioRobotics Corporation (PRCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors. This investigation follows PROCEPT's disclosure of a larger-than-expected adjusted EBITDA loss and a cut in its full-year 2026 revenue guidance, attributed partially to changes in discount practices. The firm encourages affected investors to contact them to learn more and potentially assist in the investigation without incurring any upfront costs.
How Investors May Respond To PROCEPT BioRobotics (PRCT) Winning Strong EAU Backing For Aquablation
PROCEPT BioRobotics (PRCT) recently received a strong recommendation from the European Association of Urology for its Aquablation therapy for benign prostatic hyperplasia, positioning it as a key alternative to traditional surgical options. This endorsement is expected to bolster the company's investment narrative, reinforcing its core catalyst of adoption and utilization, particularly with the international rollout of its HYDROS AI-enabled robotic system. However, investors are advised to also consider risks such as reimbursement pressures, competition, and the potential shift of BPH procedures to outpatient settings.
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims on behalf of PROCEPT BioRobotics Corporation (PRCT) shareholders. This investigation follows a significant drop in PROCEPT's stock price after the company reported a larger-than-expected adjusted EBITDA loss and cut its full-year 2026 revenue guidance. The firm encourages affected investors to contact them for more information regarding this securities investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating PROCEPT BioRobotics Corporation (PRCT) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) after the company reported a larger-than-expected adjusted EBITDA loss and cut its full-year 2026 revenue guidance. This investigation follows a stock price drop after PROCEPT attributed lower U.S. consumable revenue to a change in its discount practice. The law firm encourages affected shareholders to connect with them for further information regarding the investigation.
A Look At PROCEPT BioRobotics (PRCT) Valuation After Aquablation Wins Strong European Guideline Backing
PROCEPT BioRobotics (PRCT) is under scrutiny despite its Aquablation therapy receiving strong backing in new European guidelines for treating benign prostatic hyperplasia, as the company has seen significant share price losses over the past one and three years. Analysts have revised price targets downwards due to Q4 misses and reduced guidance, yet the stock is still considered undervalued at $26.02 compared to a fair value of $32.50. The article encourages investors to assess the risks and rewards, particularly given the company's reliance on HYDROS and Aquablation, and its ongoing operating losses without a clear path to near-term profitability.
Europe's top urology guide strongly backs Aquablation for BPH
PROCEPT BioRobotics announced that the European Association of Urology (EAU) has upgraded Aquablation therapy to a strong surgical recommendation for benign prostatic hyperplasia (BPH) with moderate-to-severe symptoms. The EAU's decision is supported by robust clinical evidence from trials like WATER, WATER II, and WATER III, highlighting the therapy's effectiveness across various prostate anatomies and its ability to preserve ejaculatory function. This endorsement positions Aquablation as a strong alternative to traditional procedures like TURP and builds on existing international clinical validations, including support from the UK's NICE for routine NHS use.
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of PROCEPT BioRobotics Corporation (PRCT) stockholders following a disclosed larger-than-expected adjusted EBITDA loss and a cut in full-year 2026 revenue guidance. The firm encourages investors who purchased PROCEPT securities to inquire about this ongoing securities investigation. This investigation comes after PROCEPT's stock price dropped due to changes in its discounting practices affecting consumable revenue.
PROCEPT BioRobotics (NASDAQ:PRCT) EVP Kevin Waters Sells 706 Shares
PROCEPT BioRobotics EVP Kevin Waters recently sold 706 shares of the company's stock for approximately $19,874, reducing his stake by 0.46%. This follows an earlier sale of 6,721 shares. The company also reported Q4 earnings that missed analyst expectations, leading several firms to lower their price targets for PRCT.
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock
Alaleh Nouri, EVP at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 5,363 shares of the company's common stock for approximately $139,230. These sales were executed under a Rule 10b5-1 trading plan. The company's stock has declined by 56% over the past year, though InvestingPro analysis suggests it may be undervalued.
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock
Alaleh Nouri, EVP at PROCEPT BioRobotics Corp, sold 5,363 shares of PRCT stock for approximately $139,230 on March 19, 2026. This sale was conducted under a Rule 10b5-1 trading plan. The company recently launched its HYDROS Robotic System in the UK and appointed Daniel Puckett to its board, while analysts have issued various ratings and price targets for the stock.
PROCEPT BioRobotics (NASDAQ: PRCT) EVP completes 5,363-share planned sale
PROCEPT BioRobotics Corp's Executive Vice President and Chief Legal Officer, Alaleh Nouri, sold a total of 5,363 shares of common stock through two open-market transactions on March 19, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. Following these transactions, Nouri directly holds 105,354 shares, indicating that the sold shares represent a relatively small portion of her total holdings.
Waters Kevin, EVP, CFO of Procept Biorobotics, sells $19,876 in PRCT
Kevin Waters, EVP and CFO of PROCEPT BioRobotics, sold 706 shares worth $19,876 to cover tax obligations from vested restricted stock units. Following this transaction, Waters still directly owns 151,558 shares. Despite a 54.72% decline in stock price over the past year, InvestingPro analysis indicates that the company is undervalued, holding more cash than debt, and possessing liquid assets exceeding short-term obligations.
Alalah Nouri (NASDAQ: PRCT) files Form 144 to sell vested RSUs
Alalah Nouri, an affiliate of PROCEPT BioRobotics Corp (NASDAQ: PRCT), has filed a Form 144 notice indicating a proposed sale of company common stock derived from RSU vesting. The filing details proposed sales of 2,820, 1,996, and 547 shares linked to RSU vesting dates in March 2026 and also notes a prior sale of 3,243 shares on March 10, 2026. This informational filing notifies market regulators of planned dispositions of vested RSUs, with compliance dependent on Rule 144 conditions.
PROCEPT BioRobotics (PRCT) CLO sells 304 shares to cover RSU taxes
PROCEPT BioRobotics' Chief Legal Officer, Alaleh Nouri, sold 304 shares of common stock at $28.1532 per share. This sale was explicitly made to cover tax withholding obligations associated with the vesting of restricted stock units. After this transaction, Nouri still holds 110,717 shares, indicating this was a minor, tax-related adjustment rather than a discretionary reduction in her holdings.
PROCEPT (NASDAQ: PRCT) CFO sells 706 shares for tax withholding
PROCEPT BioRobotics Corp's EVP and CFO, Kevin Waters, sold 706 shares of company common stock at an average price of $28.1532 per share on March 17, 2026. This transaction was executed solely to cover tax withholding obligations related to the vesting of Restricted Stock Units, categorizing it as a routine, non-discretionary event. Following the sale, Waters still retains direct ownership of 151,558 shares of PROCEPT BioRobotics stock.
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock
Alaleh Nouri, EVP at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 5,363 shares of company stock for approximately $139,230, despite the stock being down 56% over the past year. This transaction was conducted under a Rule 10b5-1 trading plan. The company recently launched its HYDROS Robotic System in the UK and made a board appointment, while analysts maintain varying ratings and price targets for PRCT.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PROCEPT BioRobotics Corporation (PRCT) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into PROCEPT BioRobotics Corporation (PRCT) following a significant stock price drop. The investigation comes after PROCEPT reported a larger-than-expected adjusted EBITDA loss and cut its full-year 2026 revenue guidance, attributing the changes partly to discontinuing discounts on bulk purchases. The firm is encouraging investors who purchased PROCEPT securities to learn more and potentially assist in the investigation.
PROCEPT BioRobotics Corporation (PRCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors. This investigation follows PROCEPT's disclosure of a larger-than-expected adjusted EBITDA loss and a cut in its full-year 2026 revenue guidance after eliminating bulk purchase discounts. Shareholders are encouraged to contact the firm for more information regarding the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating PROCEPT BioRobotics Corporation (PRCT) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors. This investigation follows PROCEPT's disclosure of a larger-than-expected adjusted EBITDA loss and a cut in its full-year 2026 revenue guidance. The firm encourages investors who purchased PROCEPT securities to contact them for more information and to assist with the investigation.
Restricted stock vesting notice at PRCT (NASDAQ: PRCT) with prior insider sale
PROCEPT BioRobotics Corp (NASDAQ: PRCT) filed a Form 144 notice regarding a proposed sale of common stock linked to a restricted stock vesting event on March 16, 2026. The filing also disclosed a prior sale by Kevin Waters of 6,721 shares on March 6, 2026, for $159,300.47. This Form 144 serves as a regulatory notification for intended sales by insiders or affiliates due to vesting, with actual execution details to be reported later.
PRCT (NASDAQ) insider sale of 6,892 shares; 304 restricted shares vested
Alaleh Nouri, an insider at PROCEPT BioRobotics Corp (PRCT), executed a Form 144 sale of 6,892 common shares for $163,353.49 on March 6, 2026. Additionally, 304 restricted shares vested as compensation on March 16, 2026. The transaction is described as routine and administrative by Rhea-AI and an Equity Transactions Specialist.
Alaleh Nouri, EVP at Procept Biorobotics, sells $139k in PRCT stock By Investing.com
Alaleh Nouri, EVP at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 5,363 shares of common stock for approximately $139,230 on March 19, 2026. These transactions were executed under a Rule 10b5-1 trading plan. The company recently launched its HYDROS Robotic System in the UK and appointed Daniel Puckett to its board, while analysts maintain varying price targets for the stock.
Why PROCEPT BioRobotics (PRCT) Is Up 10.8% After Expanding Its AI-Enabled HYDROS System Internationally
PROCEPT BioRobotics (PRCT) saw a 10.8% stock increase following its international expansion of the AI-enabled HYDROS Robotic System, which delivers Aquablation therapy for benign prostatic hyperplasia. This move supports broader adoption of their technology, although the company's reliance on a single platform in a competitive market remains a significant risk. The addition of Daniel Puckett to the board is seen as a positive step for managing growth and financial strategy, as the company is still unprofitable but has strong revenue forecasts.
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors. This investigation follows PROCEPT's disclosure of a larger-than-expected adjusted EBITDA loss and a reduced full-year 2026 revenue guidance. The firm encourages stockholders to inquire about the securities investigation and potentially assist.
Bronstein, Gewirtz & Grossman, LLC Encourages PROCEPT BioRobotics Corporation (PRCT) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC has launched a securities investigation into PROCEPT BioRobotics Corporation (NASDAQ:PRCT) on behalf of investors. This follows PROCEPT's disclosure of a larger-than-expected adjusted EBITDA loss and a cut to its full-year 2026 revenue guidance, leading to a stock price drop. The firm is encouraging affected investors to inquire about potential claims.
Thematics Asset Management Raises Stock Position in PROCEPT BioRobotics Corporation $PRCT
Thematics Asset Management significantly increased its stake in PROCEPT BioRobotics Corporation (PRCT) by 59.6% in the third quarter, now holding 630,053 shares valued at around $22.49 million. This adjustment makes up about 1.13% of PROCEPT BioRobotics, even as the company recently missed earnings and revenue estimates and maintains a "Hold" consensus rating from MarketBeat. Insider activity was mixed, with an EVP selling shares while a director made a substantial purchase, contributing to insiders owning 6.60% of the company.
Assessing PROCEPT BioRobotics (PRCT) Valuation After HYDROS Robotic System Expansion News
PROCEPT BioRobotics (PRCT) is gaining attention after expanding its HYDROS Robotic System internationally, specifically starting with the UK. Despite a recent short-term stock recovery, longer-term shareholders have seen significant value erosion. While analysts have revised down their price target for PRCT, it still suggests the stock is undervalued, though its P/S ratio is higher than industry averages.
Prosight Management LP Takes $2.75 Million Position in PROCEPT BioRobotics Corporation $PRCT
Prosight Management LP initiated a new $2.75 million position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during Q3 2025, making it their 29th largest holding. This comes as several other institutions also significantly increased their stakes, pushing institutional ownership to nearly 90%. However, PROCEPT BioRobotics recently missed quarterly earnings and revenue expectations, leading to analyst price target reductions and an average "Hold" rating.
PROCEPT BioRobotics Corp (PRCT) Trading 4.31% Higher on Mar 13
PROCEPT BioRobotics Corp (PRCT) saw its shares surge by 4.31% on March 13, reaching an intraday high of $27.28 before closing at $27.25. Wall Street analysts predict an average one-year target price of $32.92, implying a 20.82% upside, with a consensus "Outperform" recommendation. GuruFocus estimates a one-year fair value of $126.30 for PRCT, suggesting a substantial 363.57% upside from its current price.
FMR LLC Reduces Stake in PROCEPT BioRobotics Corp by 65.40%
FMR LLC, known as Fidelity, has significantly reduced its stake in PROCEPT BioRobotics Corp (PRCT) by 65.40%, selling over 3 million shares at $22.67. This move reflects a strategic reevaluation despite PROCEPT BioRobotics Corp being deemed "significantly undervalued" with strong revenue growth. The medical devices company, specializing in urology robotics, shows mixed financial indicators, leading to a cautious approach from the investment giant.
AI-guided BPH treatment robot launches in UK for men on long-term meds
PROCEPT BioRobotics has launched its HYDROS Robotic System in the UK, marking its first international expansion for treating benign prostatic hyperplasia (BPH). The system utilizes AI-interpreted real-time ultrasound and robotic precision to provide personalized Aquablation therapy, aiming to deliver durable symptom relief while preserving sexual and urinary function. The company plans further international expansion in 2026.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against PROCEPT BioRobotics Corporation (PRCT) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into PROCEPT BioRobotics Corporation (PRCT) following the company's disclosure of a larger-than-expected adjusted EBITDA loss and reduced full-year 2026 revenue guidance. The firm is encouraging stockholders who purchased PROCEPT securities to contact them to assist with the investigation. This action comes after PROCEPT's stock price dropped following their Q4 and full-year 2025 results announcement on February 25, 2026.
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
PROCEPT BioRobotics has launched its HYDROS Robotic System internationally, starting with the UK, to provide AI-enabled Aquablation therapy for benign prostatic hyperplasia (BPH). This next-generation system uses AI-interpreted ultrasound and advanced image-guided treatment planning for precise and personalized treatment. The therapy aims to offer durable symptom relief while preserving sexual and urinary function, addressing a critical need for BPH patients.
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
PROCEPT BioRobotics® has launched its HYDROS® Robotic System internationally, starting in the UK, to broaden access to AI-enabled Aquablation® therapy for benign prostatic hyperplasia (BPH). This next-generation platform uses AI-interpreted ultrasound imaging and robotic precision to provide personalized, anatomy-specific treatment. The system aims to offer durable symptom relief while preserving sexual and urinary function, addressing a significant concern for men with BPH.
PROCEPT BioRobotics (NASDAQ:PRCT) Trading Up 7.2% - Time to Buy?
PROCEPT BioRobotics (NASDAQ:PRCT) saw its stock trade up 7.2% intraday on Wednesday, despite missing quarterly earnings and revenue expectations. The company reported an EPS of ($0.53) against a consensus of ($0.32) and revenue of $76.38 million versus an estimated $93.7 million, with an average analyst rating of "Hold" and a target price of $40.82. Recent insider activity shows both sales by an EVP and significant purchases by a director.
[144] PROCEPT BioRobotics Corp SEC Filing
This article details a Form 144 SEC filing by PROCEPT BioRobotics Corp (PRCT) on March 10, 2026, for the proposed sale of securities. The filing indicates the sale of 3,243 shares by the Issuer, with an aggregate market value of $81,918, through J.P. Morgan Securities LLC on the Nasdaq exchange. The securities were acquired on March 10, 2026, via RSU Vest.
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into PROCEPT BioRobotics Corporation (PRCT) following a significant drop in its stock price. The investigation comes after Procept announced larger-than-expected adjusted EBITDA losses and cut its full-year 2026 revenue guidance. Shareholders who incurred losses are encouraged to contact the firm to inquire about potentially recovering their investments.
PROCEPT BioRobotics Corporation (PRCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors. This investigation follows PROCEPT's disclosure of a larger-than-expected adjusted EBITDA loss and a reduction in its full-year 2026 revenue guidance, leading to a drop in its stock price. The firm encourages investors who purchased PROCEPT securities to contact them for more information and to assist in the investigation.
Is PROCEPT’s Growth Targets And New CFO Director Altering The Investment Case For PROCEPT BioRobotics (PRCT)?
PROCEPT BioRobotics (PRCT) recently released its Q4 and full-year 2025 results, outlining 2026 guidance with revenue projections of US$390-US$410 million and a net loss, along with 2027 targets for significant revenue growth and improved gross margin. The company also appointed former Shockwave Medical CFO Daniel Puckett to its board, reinforcing financial oversight. While these updates sharpen the focus on execution and financial discipline, the core investment narrative still hinges on Aquablation expansion and managing ongoing losses.
